Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 7/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | MAT2A | P31153 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NT5E | P21589 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL384450 | 0.92 | PIN1 (0.51) | PIN1CDK2KMT2AGSK3AGSK3B | |
| SCHEMBL23452638 | 0.91 | PIN1 (0.52) | PIN1CDK2KMT2AGSK3AGSK3B | |
| SCHEMBL1804937 | 0.86 | PIN1 (0.56) | PIN1CDK2KMT2AGSK3AGSK3B | |
| SCHEMBL27413443 | 0.84 | KMT2A (0.54) | PIN1CDK2KMT2AGSK3AGSK3B | |
| SCHEMBL382894 | 0.84 | KMT2A (0.57) | PIN1CDK2KMT2AGSK3AGSK3B | |
| SCHEMBL1265235 | 0.83 | PIN1 (0.45) | PIN1CDK2GSK3AGSK3B | |
| SCHEMBL1265238 | 0.83 | PIN1 (0.45) | PIN1CDK2GSK3AGSK3B | |
| SCHEMBL1265237 | 0.83 | PIN1 (0.45) | PIN1CDK2GSK3AGSK3B | |
| SCHEMBL8301782 | 0.83 | KMT2A (0.59) | PIN1CDK2KMT2AGSK3AGSK3B | |
| SCHEMBL29175759 | 0.83 | KMT2A (0.59) | PIN1CDK2KMT2AGSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130034495-A1 | ISOTOPOLOGUES OF 4-[9-(TETRAHYDRO-FURAN-3-YL)-8-(2,4,6-TRIFLUORO-PHENYLAMINO)-9H-PURIN-2-YLAMINO]-CYCLOHEXAN-1-OL | SIGNAL PHARMACEUTICALS, LLC | 2013-02-07 | — | — | US | disclosed |
| US-20130034495-A1 | ISOTOPOLOGUES OF 4-[9-(TETRAHYDRO-FURAN-3-YL)-8-(2,4,6-TRIFLUORO-PHENYLAMINO)-9H-PURIN-2-YLAMINO]-CYCLOHEXAN-1-OL | SIGNAL PHARMACEUTICALS, LLC | 2013-02-07 | — | — | US | disclosed |
| WO-2011071491-A1 | ISOTOPOLOGUES OF 4-[9-(TETRAHYDRO-FURAN-3-YL)-8-(2, 4, 6- TRIFLUORO-PHENYLAMINO)-9H-PURIN-2-YLAMINO]-CYCLOHEXAN-1-OL | SIGNAL PHARMACEUTICALS, LLC (US) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130034495-A1 | ISOTOPOLOGUES OF 4-[9-(TETRAHYDRO-FURAN-3-YL)-8-(2,4,6-TRIFLUORO-PHENYLAMINO)-9H-PURIN-2-YLAMINO]-CYCLOHEXAN-1-OL | DHPS, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CPT1A | PIN1 1051/4885CDK2 922/4885KMT2A 4177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.